Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest gout Stories

2011-02-11 00:00:45

Gout was known was a man's disease until a recent medical study told another story. What's happening to alter the pain condition equation? Medical science, leading edge technology and natural pain relief ingredients have found common ground in treating localized pain conditions. A new brand, MyOmega 3 plus, (http://www.goutpain.ultimizer.com), provides efficient targeted relief of inflammation and pain for 6 plus hours per application. Chicago, IL (PRWEB) February 10, 2011 In 2010,...

2011-01-27 00:02:59

A new topical formula for treatment of pain flares and chronic pain conditions is now available direct from the manufacturer. Concept Laboratories combines the best in natural pain relief ingredients with a nanotechnology breakthrough that provides cooling comfort for fibromyalgia, arthritis and even intense gout flares (http://www.goutpain.ultimizer.com). The new brand, MyOmega 3, is a deep penetrating topical pain spray and cream that relieves targeted inflammation and pain for 6 + hours...

2011-01-18 15:27:56

The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide, according to researchers at Duke University Medical Center. Osteoarthritis is a debilitating joint degeneration for which no drug has been proven to slow or halt its progression. Physicians can only offer to treat the symptoms associated with osteoarthritis, and people with the condition are often subject to a reduced quality of life. "Finding a way to...

2011-01-10 07:00:00

SAN DIEGO, Jan. 10, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has earned a $15 million milestone payment from Bayer HealthCare AG (Bayer) under the terms of their April 2009 global license agreement to develop and commercialize Ardea's mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications. This milestone was triggered by the initiation of a Phase 2 clinical study evaluating BAY 86-9766 in combination with...

2011-01-06 15:00:00

SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol. Allopurinol currently accounts for greater than 90% of the unit sales of chronic gout prescription medications; however, in controlled trials, only 30-40% of gout patients respond adequately to allopurinol as defined by the...

2010-12-09 12:35:00

BURLINGTON, Mass., Dec. 9, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2019 the acute gout drug market will triple in size to $117 million and the chronic gout drug market will reach $1.83 billion. According to the new report entitled Acute and Chronic Gout - New Agents Target Refractory Patients and Tap Market Opportunity, both markets will be driven by new high-priced biologics....

2010-12-08 07:00:00

EXTON, Pa., Dec. 8, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that although Allopurinol remains the gold standard uric acid lowering (UAL) therapy for gout in the European Union (EU), Teijin Pharma/Ipsen/Menarini's Adenuric (currently available in France, Germany and the United Kingdom) has already achieved significant market penetration. The uptake of Adenuric is particularly robust in France, where its patient share is approximately one-half that of Allopurinol in...

2010-11-30 12:36:00

EAST BRUNSWICK, N.J., Nov. 30, 2010 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it is commencing shipment of KRYSTEXXA(TM) (pegloticase) to specialty distributors and that KRYSTEXXA will be commercially available by prescription in the United States effective December 1, 2010. A PEGylated uric acid specific enzyme, KRYSTEXXA was granted approval by the Food and Drug Administration (FDA) on September 14, 2010 for the treatment of chronic gout in adult...

2010-11-29 06:26:00

SHENYANG, China, Nov. 29, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million. Pegsiticase (Uricase-PEG 20) is a pegylated recombinant uricase derived from Candida utilis,...

2010-11-23 07:00:00

EXTON, Pa., Nov. 23, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the recent publication of a syndicated report, TreatmentTrends®: Gout. This biannual report provides a comprehensive market overview of current and future treatment trends in gout based on a primary research study fielded among 60 primary care physicians (PCPs) and 123 rheumatologists in the U.S. The report focuses on chronic and acute therapies, perceived strengths and...